Pharmacia NasalCrom Expanded Use In Young Children Approved By FDA
This article was originally published in The Tan Sheet
Executive Summary
Pharmacia will use a professional detailing force to notify allergists about NasalCrom nasal spray's newly approved indication for use in children ages two to five.
You may also be interested in...
Generic cromolyn sodium
Bausch & Lomb receives FDA clearance for private label OTC nasal solution July 3. B&L's application (ANDA 75-702) appears to be first approved by agency for generic equivalent to Pharmacia's NasalCrom, which lost marketing protection July 3, 2000 after receiving six months of pediatric exclusivity. Perrigo said it will introduce a cromolyn sodium product this year. In late March, Pharmacia received approval of a new age indication for NasalCrom, allowing for use in children ages two to five (1"The Tan Sheet" April 9, p. 11)
Generic cromolyn sodium
Bausch & Lomb receives FDA clearance for private label OTC nasal solution July 3. B&L's application (ANDA 75-702) appears to be first approved by agency for generic equivalent to Pharmacia's NasalCrom, which lost marketing protection July 3, 2000 after receiving six months of pediatric exclusivity. Perrigo said it will introduce a cromolyn sodium product this year. In late March, Pharmacia received approval of a new age indication for NasalCrom, allowing for use in children ages two to five (1"The Tan Sheet" April 9, p. 11)
Generic cromolyn sodium
Bausch & Lomb receives FDA clearance for private label OTC nasal solution July 3. B&L's application (ANDA 75-702) appears to be first approved by agency for generic equivalent to Pharmacia's NasalCrom, which lost marketing protection July 3, 2000 after receiving six months of pediatric exclusivity. Perrigo said it will introduce a cromolyn sodium product this year. In late March, Pharmacia received approval of a new age indication for NasalCrom, allowing for use in children ages two to five (1"The Tan Sheet" April 9, p. 11)